Nemours Children’s Health System, a Florida-based health system with locations in six states, is now using in-house medical 3-D printing technology to create surgical models utilizing a U.S. Food and Drug Administration (FDA)-approved segmentation software. The software helps surgeons plan complex multidisciplinary cases in interventional radiology, cancer surgery and cardiac surgery. These models serve as a pre-planning blueprint and roadmap for Nemours surgeons and proceduralists, increasing confidence, reducing procedure times and minimizing unexpected findings while in the operating room.

Emerging medical device company Emboline Inc. announced it has completed a Series B funding round totaling over $10 million for its total embolic protection device for transcatheter aortic valve replacement (TAVR) procedures. The funding includes $3 million in new equity financing from multiple investors led by SV Tech Ventures and Shangbay Capital, and over $7 million in conversion of previously-issued convertible notes.

The skin presents a formidable barrier to life-saving defibrillators, but a team of students from Rice University believes it has found a way around that problem.

Medtronic plc announced U.S. Food and Drug Administration (FDA) approval to begin an investigational device exemption (IDE) pivotal trial to evaluate the Symplicity Spyral renal denervation system in patients with high blood pressure (hypertension). Renal denervation is a minimally invasive procedure intended to regulate the activity of nerves that lead to and from the kidney, which plays an important role in managing blood pressure. The SPYRAL HTN Pivotal Trial is part of the broader SPYRAL HTN Global Clinical Program, a multi-phased clinical study strategy aimed to establish the safety and efficacy of renal denervation to lower blood pressure.